Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy

  • Kaewbubpa, Walennee (Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University) ;
  • Areepium, Nutthada (Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University) ;
  • Sriuranpong, Virote (Department of Medicine, Faculty of Medicine, Chulalongkorn University)
  • Published : 2016.11.01


For advanced non-small-cell lung cancer (NSCLC) cases, a platinum-based regimen is the first-line chemotherapy treatment. The excision repair cross-complementing group 1 (ERCC1) plays an important role in DNA repair and has been related to resistance to platinum chemotherapy. This study aimed to investigate the effects of the ERCC1 (C118T) polymorphism on treatment response in 26 Thai advanced NSCLC patients receiving first line platinum-based chemotherapy during January to July 2015 at King Chulalongkorn Memorial Hospital (KCMH). DNA was extracted from peripheral blood lymphocytes and the single nucleotide polymorphism of ERCC1 was genotyped using a real-time PCR method with the TaqMan assay. The distribution of C/C, C/T and T/T genotypes was 57.7 %, 34.6 % and 7.7 %, respectively. The response rate to platinum-based chemotherapy in the wild type (C/C) of ERCC1 (C118T) was better than with the variant types (C/T and T/T) but the difference was not statistically significant (29.7% vs 9.1%, P=0.274). The results showed that a genetic polymorphism in ERCC1 might influence patient response to platinum-based chemotherapy. Further multicenter studies are now required to confirm the results of our study.


  1. Ardizzoni A, Boni L, Tiseo M, et al (2007). Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 99, 847-57.
  2. Cheng J, Ha M, Wang Y, et al (2012). A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol, 138, 231-8.
  3. Ettinger DS, Akerley W, Borghaei H, et al (2012). Non-small cell lung cancer. J Natl Compr Canc Netw, 10, 1236-71.
  4. Gossage L, Madhusudan S (2007). Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev, 33, 565-77.
  5. Li F, Sun X, Sun N, et al (2010). Association Between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol, 33, 489-94.
  6. Lord RV, Brabender J, Gandara D, et al (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
  7. Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.
  8. Rabik CA, Dolan ME (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33, 9-23.
  9. Spiro SG, Silvestri GA (2005). The treatment of advanced nonsmall cell lung cancer. Curr Opin Pulm Med, 11, 287-91.
  10. Su D, Ma S, Liu P, et al (2007). Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 56, 281-8.
  11. Yu Q, Han J, Pan J (2007). The relationship between the polymorphisms of gene XGP and MDR1 and the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy. Practical J Cancer, 22, 252-6.